

CITATION REPORT

List of articles citing

Immunogenicity of therapeutic proteins: clinical implications and future prospects

DOI: 10.1016/s0149-2918(02)80075-3

Clinical Therapeutics, 2002, 24, 1720-40; discussion 1719.

Source: <https://exaly.com/paper-pdf/34277402/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
475	Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. 2003 , 19, 433-4		20
474	[Preclinical evaluation of the safety of biotechnology products: specific aspects]. 2003 , 58, 139-43		
473	Secreted immunomodulatory viral proteins as novel biotherapeutics. 2004 , 173, 4765-74		98
472	Infliximab. 2004 , 17, 409-26		32
471	The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?. 2004 , 125, 117-27		40
470	Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. 2004 , 73, 389-96		39
469	When biotech proteins go off-patent. 2004 , 22, 406-10		56
468	A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers. 2004 , 44, 264-9		19
467	Minimizing the immunogenicity of protein therapeutics. 2004 , 9, 82-90		145
466	Immunogenicity of interferon beta: differences among products. 2004 , 251 Suppl 2, II15-II24		53
465	Antibody pharmacokinetics and pharmacodynamics. 2004 , 93, 2645-68		684
464	Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. 2004 , 22, 437-47, ix		20
463	Biodegradable PEGylated microspheres and nanospheres. 2004 , 2, 157-171		14
462	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. 2004 , 51, 534-42		464
461	Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. 2004 , 363, 1768-71		112
460	A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. <i>Clinical Therapeutics</i> , 2004 , 26, 511-21	3.5	24
459	Neue Biopharmazeutika durch Manipulation pharmakologischer Parameter. 2004 , 52, 682-687		4

458	Study of human von Willebrand factor immunogenicity in pigs with severe von Willebrand disease. 2005 , 16, 187-92	1
457	Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. 2005 , 39, 364-75	68
456	Anticalins as an alternative to antibody technology. 2005 , 5, 1453-62	27
455	Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". 2005 , 10, 23-33	138
454	Differential reactivity of anti-primate and anti-human secondary antibodies against human and monkey immunoglobulins: implications for determining the sensitivity of immunogenicity assays. 2005 , 303, 76-80	1
453	Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. 2005 , 116, 710-9	68
452	Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. 2005 , 94, 256-74	83
451	Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: a prototypical example of biopharmaceutical aggregation. 2005 , 94, 2749-63	7
450	Current methods for detecting antibodies against erythropoietin and other recombinant proteins. 2005 , 12, 28-39	39
449	Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. 2005 , 313, 578-85	111
448	A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. 2005 , 4, 1791-800	66
447	Evolution of highly active enzymes by homology-independent recombination. 2005 , 102, 10082-7	48
446	A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. 2005 , 11, 573-82	67
445	Factors of importance for a successful delivery system for proteins. 2005 , 2, 1029-37	31
444	Anticalins in drug development. 2005 , 19, 279-88	3
443	Laboratory-directed protein evolution. 2005 , 69, 373-92	147
442	Immunologic mechanisms of EPO-associated pure red cell aplasia. 2005 , 18, 473-80	60
441	Identification of formaldehyde-induced modifications in proteins: reactions with insulin. 2006 , 17, 815-22	140

440	Blood. 2006 , 1	1
439	Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m ² PEG asparaginase in children with ALL treated according to protocol COALL-06-97. 2006 , 46, 18-25	34
438	Biosimilars: how similar or dissimilar are they?. 2006 , 11, 341-6	63
437	Issues related to targeted delivery of proteins and peptides. 2006 , 8, E466-78	82
436	Recombinant human erythropoietin in the treatment of nonrenal anemia. 2006 , 85, 69-78	8
435	Characteristic Changes in Anti-erythropoietin Antibodies in a Peritoneal Dialysis Patient Who Developed Pure Red Cell Aplasia. 2006 , 8, 71-74	1
434	Scientific and regulatory considerations on the immunogenicity of biologics. 2006 , 24, 274-80	148
433	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728	2
432	Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. 2006 , 95, 358-71	76
431	Recent developments with B-cell epitope identification for predictive studies. 2006 , 3, 137-49	34
430	Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. 2006 , 177, 8822-34	91
429	Inducing tolerance to a soluble foreign antigen by encapsulated cell transplants. 2006 , 13, 447-56	8
428	A role for protein misfolding in immunogenicity of biopharmaceuticals. 2007 , 282, 2229-36	124
427	Neutralizing antibodies and interferon treatment of multiple sclerosis: addressing the open questions. 2007 , 13, 5-7	0
426	Fabry nephropathy and the case for adjunctive renal therapy. 2007 , 18, 2426-8	8
425	Neutralizing antibodies in MS therapy: reviewing the Rebif experience. 2007 , 13, 8-13	2
424	Lesson learned from Eprex-associated pure red cell aplasia. 2007 , 30 Suppl 1, 9-12	4
423	Non-Antibody Scaffolds. 467-499	1

422	Induction of indefinite cardiac allograft survival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibitor-1 (Serp-1) treatment. 2007 , 84, 1158-67	24
421	The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. 2007 , 13, 355-62	18
420	Risks and benefits of erythropoiesis-stimulating agents in cancer management. 2007 , 44, 157-65	14
419	Cytokines in Human Health. 2007 ,	7
418	Preclinical Approaches for the Safety Assessment of Cytokines. 2007 , 175-191	
417	Immunogenicity Issues in the Development of Therapeutic Proteins. 2007 , 21, 207-216	5
416	A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. 2007 , 23, 1081-92	85
415	The Rebif new formulation story: it's not trials and error. 2007 , 8, 335-48	27
414	Biological Macromolecules. 2007 , 431-447	0
413	Immunogenicity of Therapeutic Proteins. 815-833	1
412	Protein disaggregation and refolding using high hydrostatic pressure. 2007 , 82, 610-613	7
411	Polymer-drug conjugation, recent achievements and general strategies. 2007 , 32, 933-961	518
410	RNA mutagenesis yields highly diverse mRNA libraries for in vitro protein evolution. 2007 , 7, 18	14
409	A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. 2007 , 25, 555-61	215
408	The emerging role of pharmacogenomics in biologics. 2007 , 82, 466-71	40
407	TNF- α inhibitors. 2007 , 20, 251-64	37
406	Introductory note to the three-part series of papers by Basant Sharma on: immunogenicity of therapeutic proteins: how to assess and the role of pharmaceutical quality. 2007 , 25, 307-9	1
405	Immunogenicity of therapeutic proteins. Part 1: impact of product handling. 2007 , 25, 310-7	56

404	Immunogenicity of therapeutic proteins. Part 2: impact of container closures. 2007 , 25, 318-24	80
403	Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. 2007 , 25, 325-31	84
402	Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. 2007 , 166, 727-32	33
401	Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. 2008 , 97, 1386-98	42
400	Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. 2008 , 97, 3753-64	14
399	Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. 2008 , 48, 1267-81	434
398	Use of antibodies and immunoconjugates for the therapy of more accessible cancers. 2008 , 60, 1407-20	51
397	HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. 2008 , 83, 219-27	92
396	Monoclonal antibody pharmacokinetics and pharmacodynamics. 2008 , 84, 548-58	740
395	Preclinical development of therapeutic biologics. 2008 , 3, 289-97	6
394	The implications of immunogenicity for protein-based multiple sclerosis therapies. 2008 , 275, 7-17	45
393	Factors that contribute to the immunogenicity of therapeutic recombinant human proteins. 2008 , 99, 874-82	39
392	Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. 2008 , 23, 3731-7	54
391	Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. 2008 , 94, 319-25	102
390	Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars. 2008 , 97-111	6
389	The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. <i>Clinical Therapeutics</i> , 2008 , 30 Suppl B, S50-1	3-5 15
388	How to predict and prevent the immunogenicity of therapeutic proteins. 2008 , 14, 191-202	78
387	Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. 2008 , 80, 6907-14	53

386	Immunogenicity of Therapeutic Proteins and the Assessment of Risk. 475-486	1
385	Auditing protein therapeutics management by professional APCs: toward prevention of immune responses against therapeutic proteins. 2008 , 181, 1609-15	14
384	Ranibizumab for neovascular age-related macular degeneration. 2008 , 65, 1805-14	25
383	Immunogenicity of Biopharmaceuticals. 2008 ,	6
382	Infliximab in dermatological treatment: beyond psoriasis. 2008 , 8, 123-33	10
381	Biotechnology-Derived Drug Product Development. 1-32	
380	Development of Validated Neutralization Bioassays. 209-237	1
379	. 2008 ,	5
378	. 2008 ,	7
377	Infliximab for the treatment of plaque psoriasis. 2008 , 2, 115-24	18
376	Antidrug Antibody Responses in Nonclinical Studies and their Implications. 2008 , 209-215	1
375	[Therapeutic antibodies: importance of galenics for efficacy and safety]. 2009 , 25, 1063-9	0
374	Induction of Immunological Tolerance in Chicken (<i>Gallus domesticus</i>) to DT40 Cells Stably Transfected with GFP. 2009 , 46, 356-362	2
373	Electrochemiluminescence in bioanalysis. 2009 , 1, 919-35	26
372	Interferon-beta therapy monitoring in multiple sclerosis patients. 2009 , 9, 14-28	13
371	Quality and safety considerations for recombinant biological medicines: A regulatory perspective. 2009 , 21, 13-22	6
370	Immunogenicity of bone morphogenetic proteins. 2009 , 10, 443-51	50
369	Biosimilar medicines and safety: New challenges for pharmacovigilance. 2009 , 21, 5-11	0

368	Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics. 2009 , 53, 4794-800	17
367	Follow-on protein products: scientific issues, developments and challenges. 2009 , 27, 698-705	80
366	Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. 2009 , 15, 1264-75	98
365	Protein aggregation: pathways, induction factors and analysis. 2009 , 98, 2909-34	592
364	Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout. 2009 , 98, 3548-61	33
363	Precipitation of a monoclonal antibody by soluble tungsten. 2009 , 98, 3290-301	81
362	Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. 2009 , 98, 4480-4	23
361	Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. 2009 , 98, 3218-38	107
360	Highly frequent anti-idiotypic antibody in cynomolgus monkeys developed against mouse-derived regions of anti-Fas antibody humanized by complementarity determining region grafting. 2009 , 158, 548-57	3
359	How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. 2009 , 25, 280-6	59
358	Ultrafiltration concentration of monoclonal antibody solutions: Development of an optimized method minimizing aggregation. 2009 , 342, 50-59	48
357	Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. 2009 , 61, 977-85	64
356	Proteins and Peptides. 2009 ,	5
355	Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. 2009 , 81, 8715-23	64
354	Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. 2009 , 6, 1219-30	93
353	Protein PEGylation, basic science and biological applications. 2009 , 11-31	33
352	Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation. 2009 , 47-73	1
351	Construction of a human antibody domain (VH) library. 2009 , 525, 81-99, xiii	22

350	Assessing the risk of undesirable immunogenicity/allergenicity of plant-derived therapeutic proteins. 2009 , 483, 325-39	3
349	Methods in molecular biology. Therapeutic antibodies. Methods and protocols. Preface. 2009 , 525, vii-viii, xiii	9
348	Recombinant Proteins From Plants. 2009 ,	4
347	Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. 2009 , 1, 377-81	21
346	Encyclopedia of Cancer. 2008 , 2573-2573	
345	Dealing with immunogenicity of biologicals: assessment and clinical relevance. 2009 , 21, 211-5	138
344	Ligand-Binding Assays to Support Disposition Studies of Macromolecular Therapeutics. 15-37	
343	Development and Validation of Immunogenicity Assays for Preclinical and Clinical Studies. 193-238	1
342	Manufacturing Specialties. 2010 , 1	
341	Biosimilars: current status and future directions. 2010 , 10, 1011-8	53
340	HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. 2010 , 51, 252-4	40
339	Implications of available design space for identification of non-immunogenic protein therapeutics. 2010 , 12, 283-6	2
338	Optimization algorithms for functional deimmunization of therapeutic proteins. 2010 , 11, 180	40
337	Recombinant murine growth hormone from E. coli inclusion bodies: expression, high-pressure solubilization and refolding, and characterization of activity and structure. 2010 , 26, 743-9	17
336	Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. 2010 , 31, 253-63	72
335	Aggregation of a monoclonal antibody induced by adsorption to stainless steel. 2010 , 105, 121-9	77
334	On developing a process for conducting extractable-leachable assessment of components used for storage of biopharmaceuticals. 2010 , 99, 2209-18	28
333	Kinetic analysis of a monoclonal therapeutic antibody and its single-chain homolog by surface plasmon resonance. 2010 , 396, 59-68	12

332	Foamed surfactant solution as a template for self-setting injectable hydroxyapatite scaffolds for bone regeneration. 2010 , 6, 876-85	72
331	Prediction of therapeutic index of antibody-based therapeutics: mathematical modeling approaches. 330-343	
330	Trace levels of innate immune response modulating impurities (IIRMI)s synergize to break tolerance to therapeutic proteins. 2010 , 5, e15252	41
329	A protein's conformational stability is an immunologically dominant factor: evidence that free-energy barriers for protein unfolding limit the immunogenicity of foreign proteins. 2010 , 185, 4199-205	40
328	Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. 2010 , 285, 9090-9	27
327	Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals. 2010 , 5, 287-92	12
326	Immunogenicity of osteogenic protein 1: results from a prospective, randomized, controlled, multicenter pivotal study of uninstrumented lumbar posterolateral fusion. 2010 , 13, 484-93	6
325	Safety of therapeutic monoclonal antibodies. 2010 , 5, 275-86	14
324	Immunogenicity of therapeutics: a matter of efficacy and safety. 2010 , 5, 1067-79	23
323	Are biosimilars really generics?. 2010 , 10, 489-94	15
322	On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. 2010 , 30, 767-75	66
321	Clinical pharmacokinetics of therapeutic monoclonal antibodies. 2010 , 49, 493-507	441
320	A temperature-responsive antibody-like nanostructure. 2010 , 11, 2087-93	21
319	The humanness of macaque antibody sequences. 2010 , 396, 1439-50	28
318	Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010 , 76, 351-6	5-7 97
317	Antibody Engineering. 2010 ,	4
316	Adverse Drug Reactions. 2010 ,	4
315	Mechanisms of adverse drug reactions to biologics. 2010 , 453-74	29

314	Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. 2010 , 26, 1637-45		22
313	Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. 2011 , 29, 615-24		114
312	Immunogenicity Assay Development and Validation. 2011 , 487-499		
311	Encyclopedia of Cancer. 2011 , 3160-3160		
310	Immunogenicity 2011 , 45-56		
309	Les biosimilaires. 2011 ,		
308	Encyclopedia of Cancer. 2011 , 3198-3203		
307	Comparison of analytical methods to detect instability of etanercept during thermal stress testing. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011 , 78, 213-21	5-7	20
306	Exploiting bias in a non-immune human antibody library to predict antigenicity. 2011 , 24, 845-53		1
305	The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. 2011 , 29, 735-41		584
304	. 2011 ,		6
303	A primate as an animal model for reproductive and developmental toxicity testing. 2011 , 207-218		
302	Follow-On Protein Products. 2011 , 521-529		1
301	Genetically engineered alginate lyase-PEG conjugates exhibit enhanced catalytic function and reduced immunoreactivity. 2011 , 6, e17042		19
300	Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine. 2011 , 36, 2158-67		17
299	Competitive Ligand-Binding Assays for the Detection of Neutralizing Antibodies. 2011 , 175-192		8
298	Monoclonal antibodies: interspecies scaling with minimal preclinical information. 2011 , 2, 359-68		9
297	Use of biological molecules in the treatment of inflammatory bowel disease. 2011 , 270, 15-28		26

296	A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. 2011 , 59, 334-42	25
295	Effects of shear on proteins in solution. 2011 , 33, 443-56	131
294	Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. 2011 , 28, 2393-402	90
293	Immunogenicity of therapeutic proteins: the use of animal models. 2011 , 28, 2379-85	128
292	Treatment of multiple sclerosis: current concepts and future perspectives. 2011 , 258, 1747-62	43
291	Impact of product-related factors on immunogenicity of biotherapeutics. 2011 , 100, 354-87	248
290	Effects of surfaces and leachables on the stability of biopharmaceuticals. 2011 , 100, 4158-70	108
289	Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange. 2011 , 100, 4215-24	8
288	Flow cytometry: a promising technique for the study of silicone oil-induced particulate formation in protein formulations. 2011 , 410, 191-9	70
287	Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry. 2011 , 54, 286-94	63
286	Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. 2011 , 96, 1695-702	106
285	Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. 2011 , 108, 1272-7	102
284	Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. 2011 , 68, 480-7	43
283	Large-scale production of functional human serum albumin from transgenic rice seeds. 2011 , 108, 19078-83	153
282	Strategies to estimate and improve drug tolerance in anti-drug antibody assays. 2012 , 4, 1999-2012	6
281	Clinical pharmacology considerations in biologics development. 2012 , 33, 1339-47	56
280	Design and analysis of immune-evading enzymes for ADEPT therapy. 2012 , 25, 613-23	32
279	Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity. 2012 , 4, 2725-35	9

278	Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. 2012 , 35, 215-23		21
277	Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. 2012 , 287, 25266-79		172
276	Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. 2012 , 7, 1473-84		100
275	The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists. 2012 , 31, 1281-7		7
274	Production of particles of therapeutic proteins at the air-water interface during compression/dilation cycles. 2012 , 8, 10329		72
273	Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. 2012 , 4, 2169-77		27
272	Factors associated with the loss of response to infliximab in patients with Crohn's disease. 2012 , 59, 410-6		10
271	Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. 2012 , 101, 4367-82		27
270	Site-specific PEGylation at histidine tags. 2012 , 23, 248-63		57
269	Biosimilars: company strategies to capture value from the biologics market. 2012 , 5, 1393-408		53
268	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins. 2012 , 337-367		4
267	Protein Purification and its Relation to Protein Aggregation and Particles. 2012 , 335-367		
266	Long-term efficacy and safety profile of riloncept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. <i>Clinical Therapeutics</i> , 2012 , 34, 2091-103	3,5	84
265	Pharmacokinetics, immunogenicity and anticancer efficiency of <i>Aspergillus flavipes</i> L-methioninase. 2012 , 51, 200-10		28
264	Comparative binding of disulfide-bridged PEG-Fabs. 2012 , 23, 2262-77		52
263	L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia. 2012 , 167, 2144-59		36
262	[The prediction of immunogenicity of therapeutic proteins]. 2012 , 28, 82-8		0
261	A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments. 2012 , 80, 790-806		27

260	Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies. 2012 , 101, 2686-701	25
259	The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective. 2012 , 101, 3580-5	39
258	Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. 2012 , 28, 608-22	132
257	Immunogenicity of protein aggregates--concerns and realities. 2012 , 431, 1-11	159
256	Downregulation of CD40 signal and induction of TGF- β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII. 2012 , 101, 48-55	18
255	Fabry disease, enzyme replacement therapy and the significance of antibody responses. 2012 , 35, 227-43	44
254	Development of a validated liquid chromatography tandem mass spectrometry assay for a PEGylated adnectin in cynomolgus monkey plasma using protein precipitation and trypsin digestion. 2013 , 934, 1-7	19
253	The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. 2013 , 15, 172-82	26
252	Protein-Based Designs for Healthier Foods of the Future. 2013 , 9-43	
251	Salt-induced aggregation of a monoclonal human immunoglobulin G1. 2013 , 102, 377-86	25
250	Immunogenicity in biologic therapy: implications for dermatology. 2013 , 104, 471-9	27
249	Immunogenicity in Biologic Therapy: Implications for Dermatology. 2013 , 104, 471-479	1
248	Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. 2013 , 9, 164-72	292
247	Biosimilars. 2013 ,	
246	RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF- κ B activation and down regulating inflammatory cytokines. 2013 , 203, 467-79	21
245	Biological Therapeutics. 2013 , 132-142	
244	Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development. 2013 , 5, 491-500	29
243	The impact of PEGylation on protein immunogenicity. 2013 , 15, 254-9	36

242	Immunogenicity. 2013 , 37-46	
241	Ice recrystallisation inhibition by polyols: comparison of molecular and macromolecular inhibitors and role of hydrophobic units. 2013 , 1, 478-485	42
240	An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. 2013 , 27, 1081-90	21
239	Current regulatory guidelines for immunogenicity assays. 2013 , 6-17	
238	Regulatory forum opinion piece: differences between protein-based biologic products (biotherapeutics) and chemical entities (small molecules) of relevance to the toxicologic pathologist. 2013 , 41, 128-36	16
237	Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. 2013 , 5, 1041-55	27
236	Preclinical toxicity evaluation of erythrocyte-encapsulated thymidine phosphorylase in BALB/c mice and beagle dogs: an enzyme-replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy. 2013 , 131, 311-24	27
235	Conformation-dependent high-affinity potent ricin-neutralizing monoclonal antibodies. 2013 , 2013, 471346	12
234	Developments and Challenges for mAb-Based Therapeutics. 2013 , 2, 452-500	95
233	Pharmacology of AMG 181, a human anti- $\alpha 4 \beta 7$ antibody that specifically alters trafficking of gut-homing T cells. 2013 , 169, 51-68	33
232	IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers. 2013 , 102, 852-65	55
231	Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. 2013 , 5, 810-6	91
230	Chemical and Genetic Modification. 2013 , 1-52	2
229	Receptor-Fc and Ligand Traps as High-Affinity Biological Blockers: Development and Clinical Applications. 2013 , 143-162	
228	Clinical trial risk in type-2 diabetes: importance of patient history. 2014 , 17, 393-400	2
227	. 2014 ,	1
226	Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. 2014 , 74, 1047-55	28
225	Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration. 2014 , 103, 128-39	25

224	Wechselwirkungen von Proteinen mit Polymerbeschichtungen und Biomaterialien. 2014 , 126, 8138-8169		32
223	In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice. 2014 , 31, 216-27		30
222	Comprehensive evaluation of etanercept stability in various concentrations with biophysical assessment. 2014 , 460, 108-18		23
221	Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet. <i>Journal of Controlled Release</i> , 2014 , 185, 1-11	11.7	32
220	Thiol-disulfide exchange in peptides derived from human growth hormone. 2014 , 103, 1032-42		11
219	Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. 2014 , 19, 1945-52		168
218	Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1424-30	4.6	47
217	Nonclinical Safety Assessment of Biotechnology-Derived Products: Considerations and Challenges. 2014 , 405-426		
216	A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta. 2014 , 415, 17-23		5
215	One-pot Synthesis of Elastin-like Polypeptide Hydrogels with Grafted VEGF-Mimetic Peptides. 2014 , 2, 757-765		66
214	The effects of dodecyl maltoside and sodium dodecyl sulfate surfactants on the stability and aggregation of recombinant interferon Beta-1b. 2014 , 34, 894-901		10
213	Next-generation optimized biotherapeutics - A review and preclinical study. 2014 , 1844, 2053-2057		13
212	Protein interactions with polymer coatings and biomaterials. 2014 , 53, 8004-31		500
211	Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. 2014 , 16, 464-77		28
210	Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. 2014 , 16, 658-73		187
209	Production of recombinant antibodies using bacteriophages. 2014 , 4, 91-8		17
208	Aesthetic uses of the botulinum toxin. 2014 , 32, 23-36		24
207	HAHA antibodies -- not such a funny story. 2014 , 8, 439-40		1

206	Effects of pH and buffer concentration on the thermal stability of etanercept using DSC and DLS. 2014 , 37, 808-16	23
205	Biosafe nanoscale pharmaceutical adjuvant materials. 2014 , 10, 2393-419	16
204	Pharmacokinetic characteristics of therapeutic antibodies. 2015 , 13, 530-4	7
203	Pharmakokinetische Besonderheiten von therapeutischen Antikörpern. 2015 , 13, 530-534	6
202	Immunogenicity considerations. 2015 , 23-66	
201	Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4+ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants. 2015 , 104, 396-406	7
200	Assessment of the immunogenicity of mechanically induced interferon aggregates in a transgenic mouse model. 2015 , 104, 722-30	7
199	Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know. 2015 , 55, 1171-82	22
198	Original inhibition method of excessive synthesis of pro-inflammatory cytokine of tumour necrosis factor β 2015 , 40, 345-8	1
197	Biologic concentration testing in inflammatory bowel disease. 2015 , 21, 1435-42	49
196	Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering. 2015 , 84, 1-26	46
195	Stabilization of proteins in solid form. 2015 , 93, 14-24	107
194	Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo. 2015 , 22, 629-39	40
193	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. 2015 , 71, 773-99	11
192	Particle contamination of parenteralia and in-line filtration of proteinaceous drugs. 2015 , 496, 250-67	16
191	The Role of Protein Excipient in Driving Antibody Responses to Erythropoietin. 2015 , 104, 4041-4055	8
190	Biosimilars: clinical interpretation and implications for drug development. 2015 , 17, 8	3
189	Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice. 2015 , 32, 430-44	47

188	Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. 2015 , 34, 265-79	38
187	Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein. 2015 , 66, 157-62	1
186	Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?. 2015 , 26, 520-7	9
185	The immunogenicity of antibody aggregates in a novel transgenic mouse model. 2015 , 32, 2344-59	84
184	Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting. 2015 , 104, 1575-91	40
183	Effect of vaccine administration modality on immunogenicity and efficacy. 2015 , 14, 1509-23	106
182	Production of Recombinant Human scFv Against Tetanus Toxin Heavy Chain by Phage Display Technology. 2015 , 34, 303-9	1
181	Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. 2015 , 135, 31-38	61
180	Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins. 2015 , 104, 527-35	84
179	Pharmaceutical Dosage Forms - Parenteral Medications. 2016 ,	1
178	Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products. 2016 ,	7
177	Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?. 2016 , 10, 123-34	2
176	Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins. 2016 , 2016, 2342187	37
175	Aesthetic applications for botulinum toxin type A: treating the upper and lower face. 2016 , 5, 330-336	
174	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. 2016 , 22, 1999-2015	71
173	Nanopharmacy: Exploratory Methods for Polymeric Materials. 2016 , 231-270	0
172	Aspergillus flavipes methionine γ -lyase-dextran conjugates with enhanced structural, proteolytic stability and anticancer efficiency. 2016 , 133, S15-S24	20
171	Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice. 2016 , 105, 1693-1704	18

170	Optimized polypeptide for a subunit vaccine against avian reovirus. 2016 , 34, 3178-3183	8
169	The effects of a repeated dose of a recombinant humanized anti-cocaine monoclonal antibody on cocaine self-administration in rats. 2016 , 168, 287-292	10
168	Excipients Used in Biotechnology Products. 2016 , 145-198	3
167	Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics. 2016 , 18, 1335-1350	33
166	From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. 2016 , 184, 137-46	51
165	Comprehensive Discovery and Quantitation of Protein Heterogeneity via LC-MS/MS Peptide Mapping for Clone Selection of a Therapeutic Protein. 2016 , 88, 9309-17	17
164	Interferon Beta: From Molecular Level to Therapeutic Effects. 2016 , 326, 343-72	33
163	Computationally driven antibody engineering enables simultaneous humanization and thermostabilization. 2016 , 29, 419-426	7
162	Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. 2016 , 105, 1623-1632	20
161	Improvement of in vivo antimicrobial activity of HbCARD peptides by D-arginine replacement. 2016 , 100, 9125-9132	11
160	Assessing the Immunogenicity of Biopharmaceuticals. 2016 , 30, 195-206	75
159	Detection and Identification of Leachables in Vaccine from Plastic Packaging Materials Using UPLC-QTOF MS with Self-Built Polymer Additives Library. 2016 , 88, 6749-57	24
158	Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. 2016 , 299, 70-7	95
157	An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice. 2016 , 36, 192-203	3
156	Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates. 2016 , 36, 247-57	17
155	Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. 2016 , 33, 261-8	31
154	How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017 , 114, 288-295	5:7 213
153	Using endogenous ligands for direct superparamagnetic nanoparticle cluster-based body fluid exosome separation. 2017 , 7, 2926-2933	4

152	Student Award for Outstanding Research Winner in the Undergraduate Category for the 2017 Society for Biomaterials Annual Meeting and Exposition, April 5-8, 2017, Minneapolis, Minnesota: Development and characterization of stimuli-responsive hydrogel microcarriers for oral protein delivery. 2017 , 105, 1243-1251	8
151	Overcoming an optimization plateau in the directed evolution of highly efficient nerve agent bioscavengers. 2017 , 30, 333-345	41
150	A Primate as an Animal Model for Reproductive and Developmental Toxicology Testing. 2017 , 315-329	
149	Tumor necrosis factor inhibitors in psoriatic arthritis. 2017 , 10, 899-910	22
148	Routes for Drug Translocation Across the Blood-Brain Barrier: Exploiting Peptides as Delivery Vectors. 2017 , 106, 2326-2334	24
147	A comparison study of bioanalytical methods for detection and characterization of anti-velaglucerase alfa antibodies. 2017 , 9, 775-786	1
146	Botulinum Toxin: From Molecule to Medicine. 2017 , 37-51	0
145	Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins. 2017 , 106, 2946-2954	38
144	Grafting challenging monomers from proteins using aqueous ICAR ATRP under bio-relevant conditions. 2017 , 8, 3992-3998	16
143	Transmembrane TNF-dependent uptake of anti-TNF antibodies. 2017 , 9, 680-695	36
142	In Vivo Effect of Innate Immune Response Modulating Impurities on the Skin Milieu Using a Macaque Model: Impact on Product Immunogenicity. 2017 , 106, 751-760	12
141	Pharmacokinetics of Therapeutic Proteins. 2017 , 311-340	1
140	Safety Considerations for Biologics. 2017 , 341-385	
139	Discovery of human-like L-asparaginases with potential clinical use by directed evolution. <i>Scientific Reports</i> , 2017 , 7, 10224	4.9 19
138	Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. 2017 , 13, 985-995	27
137	A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. 2017 , 8, 1390	107
136	Pharmacokinetics of Monoclonal Antibodies. 2017 , 6, 576-588	309
135	Enrichment of endogenous fractalkine and anti-inflammatory cells via aptamer-functionalized hydrogels. 2017 , 142, 52-61	23

134	Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections. 2017 , 27, 283-297	44
133	Development of a P((MAA-co-NVP)-g-EG) Hydrogel Platform for Oral Protein Delivery: Effects of Hydrogel Composition on Environmental Response and Protein Partitioning. 2017 , 17, 1600266	14
132	Efficient ex vivo delivery of chemically modified messenger RNA using lipofection and magnetofection. 2017 , 482, 796-801	9
131	. 2017 ,	4
130	Cancer therapies based on enzymatic amino acid depletion. 2017 , 623-651	2
129	Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins. 2017 , 5,	8
128	Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions. 2018 , 107, 1313-1321	8
127	Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins. 2018 , 107, 1247-1260	61
126	Toxicity assessment of the extractables from multi-layer coextrusion poly ethylene bags exposed to pH=5 solution containing 4% benzyl alcohol and 0.1 M sodium acetate. 2018 , 94, 47-56	7
125	The development of biological therapies for neurological diseases: moving on from previous failures. 2018 , 13, 283-293	8
124	Immunogenicity of Biologic Agents in Psoriasis. 2018 , 93-99	
123	Higher-order structure and conformational change in biopharmaceuticals. 2018 , 93, 2477-2485	5
122	Comparison of melibiose and trehalose as stabilising excipients for spray-dried β -galactosidase formulations. 2018 , 543, 21-28	11
121	Immunogenicity and Immune-Related Adverse Drug Reactions. 2018 , 498-517	
120	Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab. 2018 , 32, 319-325	6
119	Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it. 2018 , 37, 301-315	5
118	Large molecules with large pharmacokinetic variability: progress in pursuit of key considerations for intersubject variability. 2018 , 3, 57-60	1
117	Aggregates of IVIG or Avastin, but not HSA, modify the response to model innate immune response modulating impurities. <i>Scientific Reports</i> , 2018 , 8, 11477	4.9 17

116	Inhibition of the fibrillation of highly amyloidogenic human calcitonin by cucurbit[7]uril with improved bioactivity. 2018 , 78, 178-188	18
115	Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues. 2018 , 107, 2013-2019	41
114	Immunotoxicology of Biopharmaceuticals. 2018 , 826-851	
113	Analytical Methods. 2018 , 1001-1049	
112	The case for protein PEGylation. 2018 , 27-49	6
111	Sensitivity and drug tolerance of antidrug antibody assays in relation to positive control characteristics. 2018 , 10, 1289-1306	3
110	Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH. 2019 , 11, 1569-1580	2
109	A method to induce hen egg lysozyme-specific humoral immune tolerance in mice by pre-exposition with the protein oligomers. 2019 , 20, 100679	
108	Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically. 2019 , 33, 683-691	3
107	Test models for the evaluation of immunogenicity of protein aggregates. 2019 , 559, 192-200	8
106	Immunogenicity of Protein Pharmaceuticals. 2019 , 108, 1637-1654	42
105	Lipid nanomaterials for the delivery of antimicrobial peptides. 2019 , 173-195	1
104	The Science and Regulations of Naturally Derived Complex Drugs. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2019 ,	0.5
103	Immunogenicity Risks for Naturally Derived Complex Drugs. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2019 , 219-244	0.5
102	Immunogenicity of Therapeutic Proteins. 2019 , 139-150	2
101	Biocompatibility and immunogenic response to recombinant honeybee silk material. 2019 , 107, 1763-1770	1
100	Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies. 2019 , 8,	34
99	Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin. 2019 , 39, 302-313	

98	A REVIEW ON THERAPEUTIC PROTEINS: STABILITY ASPECTS AND CLINICAL IMPLICATIONS. 2019 , 10, 1-7	0
97	Approaches to improve drug tolerance and target tolerance in the assessment of neutralizing anti-drug antibodies. 2019 , 11, 2061-2074	2
96	Insights on the Formulation of Recombinant Proteins. 2020 , 171, 23-54	0
95	Regulation of biosimilar medicines and current perspectives on interchangeability and policy. 2019 , 75, 1-11	39
94	mutagenesis: decreasing the immunogenicity of botulinum toxin type A. 2019 , 37, 4767-4778	3
93	Psoriasis moderada-grave y síndrome poliglandular autoinmune. 2019 , 34, 59-61	0
92	Decreasing the immunogenicity of arginine deiminase enzyme via structure-based computational analysis. 2019 , 37, 523-536	19
91	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. 2020 , 182, 180-189	14
90	Point Mutation Approach to Reduce Antigenicity of Interferon Beta. 2020 , 26, 1353-1361	1
89	Polymeric Micelles Loading Proteins through Concurrent Ion Complexation and pH-Cleavable Covalent Bonding for In Vivo Delivery. 2020 , 20, e1900161	23
88	Noncanonical immunomodulatory activity of complement regulator C4BP(β) limits the development of lupus nephritis. 2020 , 97, 551-566	2
87	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. 2020 , 37, 4491-4518	12
86	Evaluation of M2-like macrophage enrichment after diffuse traumatic brain injury through transient interleukin-4 expression from engineered mesenchymal stromal cells. 2020 , 17, 197	13
85	Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188. 2020 , 109, 2393-2404	9
84	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. 2020 , 108, 734-755	45
83	Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?. 2020 , 12, 1021-1031	4
82	Effects of SW033291 on the myogenesis of muscle-derived stem cells and muscle regeneration. 2020 , 11, 76	3
81	Neurotoxin Impurities: A Review of Threats to Efficacy. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2020 , 8, e2627	1.2 5

80	Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients. 2020 , 22, 199-216		20
79	Binding of excipients is a poor predictor for aggregation kinetics of biopharmaceutical proteins. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020 , 151, 127-136	5.7	7
78	Freeze-concentration of solutes during bulk freezing and its impact on protein stability. 2020 , 58, 101703		7
77	Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes. 2021 , 39, 1131-1139		4
76	Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives. 2021 , 213, 113191		1
75	Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 10781552211010928	1.7	1
74	Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. <i>International Journal of Retina and Vitreous</i> , 2021 , 7, 37	2.9	8
73	Reduction of enzymatic degradation of insulin via encapsulation in a lipidic bicontinuous cubic phase. <i>Journal of Colloid and Interface Science</i> , 2021 , 592, 135-144	9.3	3
72	Amino Acid Depletion Therapies: Starving Cancer Cells to Death. <i>Trends in Endocrinology and Metabolism</i> , 2021 , 32, 367-381	8.8	17
71	Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant human granulocyte colony-stimulating factor, in rat and monkey models. <i>Scientific Reports</i> , 2021 , 11, 12004	4.9	0
70	Immune response with long-term memory triggered by amorphous aggregates of misfolded anti-EGFR V-7D12 is directed against the native V-7D12 as well as the framework of the analogous V-9G8. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021 , 165, 13-21	5.7	0
69	Insulin Delivery Using Dynamic Covalent Boronic Acid/Ester-Controlled Release. <i>Advanced Therapeutics</i> , 2021 , 4, 2100118	4.9	2
68	Biosimilars accessible in the market for the treatment of cancer. <i>Journal of Controlled Release</i> , 2021 , 336, 112-129	11.7	20
67	Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 2565-2584	15.5	6
66	Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. <i>ACS Nano</i> , 2021 , 15, 14022-14048	16.7	25
65	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , 2021 ,	4.9	2
64	Protein and solutes freeze-concentration in water/glycerol mixtures revealed by pulse EPR. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021 , 169, 44-51	5.7	
63	Small molecules in regeneration. 2022 , 451-464		

62	Pharmacology of TNF inhibitors. 2006 , 23-44		6
61	Immune Reactions Towards Biopharmaceuticals [a] General, Mechanistic Overview. 2008 , 1-25		4
60	Presenting an Immunogenicity Risk Assessment to Regulatory Agencies. 2008 , 239-258		5
59	Models for Prediction of Immunogenicity. 2008 , 75-95		4
58	Case Study: Immunogenicity of Interferon-Beta. 2008 , 127-136		2
57	Generation, Engineering and Production of Human Antibodies Using Hucal[. 2004 , 13-52		8
56	The immunogenicity of an anti-EGFR single domain antibody (V) is enhanced by misfolded amorphous aggregation but not by heat-induced aggregation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020 , 152, 164-174	5-7	7
55	Analogue and Conformational Studies on Peptides, Hormones and Other Biologically Active Peptides. <i>Amino Acids, Peptides and Proteins</i> , 129-271	2-7	4
54	Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration. <i>Medical Science Monitor</i> , 2014 , 20, 875-83	3-2	5
53	Immunological and Toxicological Studies of Staphylococcin Bac188 (A Bacteriocin/Bacteriocin-like Inhibitory Substance) on Experimental Animals. <i>Pakistan Journal of Biological Sciences</i> , 2004 , 7, 1888-1892 ^{6,8}		
52	Antibodies in the Future. 2006 , 371-376		
51	Immunotoxicology of Biological Response Modifiers. 2010 , 521-529		1
50	Human Anti-antibody Response. 2010 , 507-515		
49	Immunotoxicology of Biopharmaceutics. 2010 , 489-519		
48	Immunogenicity of Therapeutic Proteins and the Assessment of Risk. 1		
47	Biosimilars. 1		
46	Immunogenicity of Therapeutic Proteins. 1		
45	Safety Assessment of Biotechnology-derived Therapeutics.		

- 44 Follow-on Protein Products: Scientific Issues, Developments, and Challenges. **2011**, 554-562
- 43 Immunogenicity Assay Development and Validation. **2011**, 521-534
- 42 Encyclopedia of Cancer. **2011**, 3206-3207
- 41 Selection of Optimal Adjuvants and Product Factors that Affect Vaccine Immunogenicity. 327-383
- 40 A Stepped Care Approach to the Management of Chronic Kidney Disease. **2012**, 2205-2239 1
- 39 Biopharmaceutics of NCEs and NBEs. **2012**, 30-56
- 38 Nonclinical Safety Evaluation of Drugs. **2013**, 25-54
- 37 Encyclopedia of Cancer. **2014**, 1-3
- 36 Immunotoxicology of Biopharmaceutics?. **2014**,
- 35 Quality by Design for Distribution of Environmentally Sensitive Pharmaceutical Products. *AAPS Advances in the Pharmaceutical Sciences Series*, **2015**, 353-363 0.5
- 34 Review: The Critical Role of Clinical Pharmacology in the Development of Biologics. 1-16
- 33 Prediction of Human Pharmacokinetics for Protein-Based Biologic Therapeutics. 1-16
- 32 Encyclopedia of Cancer. **2016**, 3958-3960
- 31 Immunotoxicology of Biological Response Modifiers?. **2016**,
- 30 Bispecific Antibodies. **2017**, 75-97
- 29 From Basic Immunology to Clinical Practice: Bio-Originators versus Bio-Similars. *Mediterranean Journal of Rheumatology*, **2019**, 30, 54-58 1.4
- 28 Evaluation of M2-like macrophage enrichment after diffuse traumatic brain injury through transient interleukin-4 expression from engineered mesenchymal stromal cells.
- 27 Imunogenicidade dos fármacos imunobiológicos. *Revista Paulista De Reumatologia*, **2016**, 27-37 0.1

26	Radiopharmaceutical Sciences. 2020 , 49-191		1
25	Application of Spectroscopic and Calorimetric Techniques in Protein Formulation Development. 99-123		
24	Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF- α Effect of Adalimumab. <i>Frontiers in Pharmacology</i> , 2021 , 12, 782385	5.6	0
23	Targeting Nutrient Dependency in Cancer Treatment.. <i>Frontiers in Oncology</i> , 2022 , 12, 820173	5.3	0
22	Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	1
21	Comparison between Nanoparticle Encapsulation and Surface Loading for Lysosomal Enzyme Replacement Therapy.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
20	Immunogenicity Associated with Aesthetic Botulinumtoxin A: A Survey of Asia-Pacific PhysiciansN Experiences and Recommendations.. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2022 , 10, e4217	1.2	1
19	Application of Spectroscopic and Calorimetric Techniques in Protein Formulation Development. 2006 , 99-123		
18	Inhibitors of tumor necrosis factor-alpha for treatment of psoriatic patients. <i>Vestnik Dermatologii i Venerologii</i> , 2010 , 86, 7-15	0.4	
17	Increasing the Reuse of Protein Non-Na α Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits. <i>International Journal of Toxicology</i> , 109158182211017	2.4	2
16	Enhanced protein aggregation suppressor activity of N-acetyl-L-arginine for agitation-induced aggregation with silicone oil and its impact on innate immune responses. <i>International Journal of Biological Macromolecules</i> , 2022 , 216, 42-51	7.9	0
15	Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review. <i>American Journal of Ophthalmology Case Reports</i> , 2022 , 27, 101634	1.3	0
14	Anti-drug antibodies of IL-17 inhibitors for psoriasis: a systematic review. 1-12		
13	Fabrication of succinate-alginate xerogel films for in vitro coupling of osteogenesis and neovascularization. 2022 , 141, 213122		0
12	Therapeutic Peptides in Skin and Hair Disorders. 2022 , 157-173		0
11	Biotechnology applications in clinical trials. 2022 , 163-195		0
10	Large-Scale Freeze-Thaw of Protein Solutions: Study of the Relative Contributions of Freeze-Concentration and Ice Surface Area on Stability of Lactate Dehydrogenase. 2022 ,		0
9	Engineering the right formulation for enhanced drug delivery. 2022 , 114561		1

- 8 Lipid Nanoparticles Technology in Vaccines; Shaping the Future of Prophylactic Medicine. **2022**, 113111 ○
- 7 A method for detection of anti-drug antibodies to a biotherapeutic (CSL112) with endogenous counterpart (apolipoprotein A-I) using a novel sample pre-treatment electrochemiluminescence assay. **2023**, 513, 113411 ○
- 6 Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment. 50-57 ○
- 5 Fully Oxygen-Tolerant Visible-Light-Induced ATRP of Acrylates in Water: Toward Synthesis of Protein-Polymer Hybrids. **2023**, 56, 2017-2026 ○
- 4 Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody. **2023**, 9, e13999 ○
- 3 Immunogenicity of Therapeutic Proteins. **2023**, 251-273 ○
- 2 The feasibility of the use of monoclonal antibodies to interleukin 23 in the therapy of severe psoriasis with the eluding effect of genetically engineered biological drugs. **2023**, 46-52 ○
- 1 Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease. ○